Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
Status:
Terminated
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well tivantinib works in treating patients with previously
treated malignant mesothelioma. Tivantinib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.